The Canadian Medical Isotope Ecosystem Development Fund (CMIEDF) invests in Canadian programs that advance medical isotope supply or develop emerging technologies in radiotherapeutics and diagnostics.
March 31, 2026 – The Canadian Medical Isotope Ecosystem (CMIE) is pleased to announce the successful conclusion of its third call for proposals, with five high-impact programs selected to receive a combined total of over $2 million in funding. This funding originated from the Strategic Response Fund (SRF) from Innovation Science and Economic Development (ISED) Canada.
As with the previous two calls for proposals, the selected programs align with federal priorities to strengthen Canada’s biomanufacturing and life sciences capacity, reinforce secure and resilient medical isotope supply chains, and ensure reliable domestic access to life-saving isotopes used in the diagnosis and treatment of cancer and other serious diseases. Together, these programs advance Canadian innovation while helping position Canada as a trusted global supplier of critical medical isotopes and radiopharmaceuticals.
The funded programs showcase the depth, diversity, and excellence within Canada’s medical isotope ecosystem, spanning advancements in isotope production, purification and processing, and enabling technologies to support commercialization and clinical readiness.
These targeted investments will enable the advancement of research and development activities, scale promising technologies, and strengthen partnerships across industry, academia, and government, ultimately contributing to improved patient outcomes, supply chain resilience, and long-term ecosystem sustainability.
“Our third call for proposals was the most competitive to date, underscoring both the strong demand for funding programs like the CMIE’s and the depth of medical isotope innovation taking place across Canada. The quality and volume of applications clearly demonstrates a robust pipeline of Canadian technologies with the potential to strengthen domestic supply chains, advance patient care, and reinforce Canada’s leadership in medical isotopes. Strategic investments like this ensure that the most promising innovations can move forward and deliver real impact for Canadians”
– Holly Bilton, Executive Chair, CMIE
“The impressive number of submissions received for this third call demonstrates both the depth of Canada’s medical isotope innovation pipeline and the growing readiness of these technologies for development and commercialization as innovative radiopharmaceuticals. Through the CMIE, we are helping companies derisk development, scale production, and attract follow-on investment, strengthening domestic supply chains while positioning Canadian technologies for global markets and long-term impact.”
– Owen Roberts, CEO, CPDC
“As Canada reinforces its position as a global leader in advanced industries, strategic investments in our medical isotope sector are strengthening a high-value supply chain that supports long-term economic growth. By backing Canadian companies at the forefront of this field, we’re scaling homegrown expertise, expanding domestic production capacity and reinforcing Canada’s role as a reliable partner in global markets. This announcement will fuel the growth of Canadian industry champions, support hundreds of skilled jobs and drive innovation across our economy.”
– The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions
In the coming weeks, the CMIE will shine a spotlight on each of the funded programs with detailed updates on the CMIE website and LinkedIn, providing insights into the groundbreaking work being undertaken across the country.
For more information about the CMIE and its initiatives, please visit cmie.ca, or contact funding@cmie.ca
About CMIE
The CMIE is an initiative created to accelerate R&D investment, collaboration, technology adoption and training to enable Canada to lead in the innovation of medical isotopes. Through a unique combination of co-investment, cross-industry collaboration, and IP development, we are building a strong medical isotope innovation ecosystem.
We bring together a community of Canadians from industry, academia, and government to advance medical isotopes and radiopharmaceuticals.